| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | StemRegenin 1 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |